Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
The new site enables end-to-end production of viral vector gene therapies
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
Subscribe To Our Newsletter & Stay Updated